| Previous close | 0.6018 |
| Open | 0.5911 |
| Day's range | 0.5910 to 0.6698 |
| 52-week range | 0.5600 to 52.50 |
| Volume | 384.9K |
| Average volume (3 months) | 2.74M |
| 1-year price change | -98.62% |
| Market value | 2.21M |
| EPS (last 12 months) | -1.58 |
| Beta (1 year) | 2.81 |
| Dividend yield | None |
Company figures come from SEC filings through the quarter ending Jun 30, 2026. All statistics
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
For learning only, not investment advice. Chart by TradingView. How to read a stock quote.